SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $731,749,074 |
| Positions | 14 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| CG ONCOLOGY INC | CGON | COM | $452,707,083 | 6,371,669 |
| Nuvation Bio Inc. | NUVB | COM | $147,421,214 | 25,954,439 |
| AARDVARK THERAPEUTICS INC | AARD | COM | $22,563,642 | 3,917,299 |
| Aclaris Therapeutics, Inc. | ACRS | COM | $21,380,783 | 4,041,736 |
| Upstream Bio Inc. | UPB | COM | $18,856,087 | 2,724,868 |
| Arcus Biosciences, Inc | RCUS | COM | $14,329,137 | 464,779 |
| Equillium Inc. | EQ | COM | $14,231,386 | 4,447,308 |
| REVOLUTION MEDICINES INC(NSM) | RVMD | COM | $9,863,476 | 52,667 |
| Lyell Immunopharma, Inc. | Unresolved | COM | $9,723,303 | 692,050 |
| BeyondSpring Inc. | BYSI | SHS | $6,651,229 | 3,800,702 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.